RAC 0.63% $1.59 race oncology ltd

Ann: H1 2023 Preclinical and Clinical Programs Update, page-39

  1. 20 Posts.
    lightbulb Created with Sketch. 3
    "In summary, RC220 provides Race with an assured IP basis and increased flexibility for use, making this formulation the stronger choice for multi-centre clinical studies."

    Are there concerns that RC110 IP is not assured?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.